Generics May Seek Correction Of Overly Broad Use Codes

In Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S , 132 S. Ct. 1670 (April 17, 2012) [ enhanced version available to lexis.com subscribers ], the Supreme Court unanimously held that a generic drug company may use a counterclaim provision of the Hatch-Waxman Act to seek correction of an overly broad use...